Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Thalassemia, BetaThalassemia Major

Interventions

BIOLOGICAL

VGB-Ex01

CRISPR-Cas12b editing hematopoietic stem cells

Trial Locations (1)

RECRUITING

Regenerative Medicine Center, Tianjin

All Listed Sponsors

collaborator

Shanghai Vitalgen BioPharma Co., Ltd.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER